Below, meaningful Zepbound data were not available to graph: For the time being, Novo Nordisks Ozempic remains the dominant GLP-1 product with $4.20 billion in Q2 sales, outpacing its nearest competitor, Lillys Mounjaro, by more than $1 billion
In our broader review, all studies reported weight reductions after treatment with GLP-1RAs, but the magnitude of weight loss ranged from around 1 to 20% of the pre-treatment baseline
Schedule your appointment at Aspire Medspa & Beauty Bar today and discover how this revolutionary product can help calm and rejuvenate your skin
Final Perspective The January 2026 launch of oral Wegovy represents an expansion of FDA-approved options for patients seeking medically-supervised weight management
No insurance is required, and HSA/FSA accounts cover the medication
Have you noticed unusual fullness or abdominal pressure after starting Wegovy Injection and wondered if it is normal